Adalimumab

Section: 8. Immunomodulators and antineoplastics > 8.1. Immunomodulators for non-malignant disease

EMLc | Codes ATC: L04AB04

Indication	Crohn disease site Code ICD11: DD70.Z
INN	Adalimumab
Type de médicament	Biological agent
Type de liste	Liste complémentaire
Additional notes	EML: certolizumab pegol, etanercept, golimumab and infliximab are alternatives, including quality-assured biosimilars. EMLc: etanercept and infliximab are alternatives, including quality-assured biosimilars.
Formulations	**Parenteral > General injections > SC:** 40 mg per 0.8 mL ; 40 mg per 0.4 mL ; 10 mg per 0.2 mL (EMLc) ; 20 mg per 0.4 mL (EMLc)
Historique des statuts LME	Ajouté pour la première fois en 2019 (TRS 1021) Modifié en 2023 (TRS 1049)
Sexe	Tous
Âge	Aussi recommandé pour les enfants
Équivalence thérapeutique	certolizumab pegol (Codes ATC: L04AB05) etanercept (Codes ATC: L04AB01) golimumab (Codes ATC: L04AB06) infliximab (Codes ATC: L04AB02)
Renseignements sur le brevet	Main patents have expired but secondary patents might remain active in some jurisdictions. For more information on specific patents and license status for developing countries visit www.MedsPal.org Lire la suite sur les brevets.
Balises	Biological
Wikipédia	Adalimumab
DrugBank	Adalimumab

Résumé des preuves et recommandation du comité d'experts

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended the addition of new strength formulations of adalimumab (injection 10 mg/0.2 mL and 20 mg/0.4 mL) to the EMLc.